This study describes the use of a novel, two-compartment, static, dialysis bag model to study 22 the release, diffusion and antibacterial activity of a novel, bioresponsive dextrin-colistin 23 polymer conjugate against multidrug resistant (MDR) wild-type Acinetobacter baumannii. In 24 this model, colistin sulfate, at its MIC, produced a rapid and extensive drop in viable bacterial 25
Introduction 43
In an attempt to meet the challenge of the global epidemic of antibiotic-resistant infections, 44 treatment strategies are increasingly employing nanomedicine-based approaches, which 45 have been used in the treatment of a number of human diseases with some considerable 46 success (1, 2). The adoption of these approaches as antimicrobial therapies has seen the 47 pre-clinical development of novel agents including antibiotic-bearing nanoparticles, liposomes, 48 dendrimers and polymer therapeutics (3, 4); agents which may offer potential benefits over 49 conventional systemic delivery in minimizing toxicity and overcoming drug resistance by 50 affording 'selective targeting' of systemically-delivered antibiotics to sites of infection and 51 inflammation, thus maximizing local bioavailability of the chemotherapeutic agent (3, 5). The 52 employment of 'polymer therapeutics', in which an antibiotic is covalently attached to a water-53 soluble polymer, may afford a number of important practical advantages, including increased 54 solubility and bioavailability, decreased toxicity and a chemically modifiable controlled release 55 system which can be truly "customized" (2, 4, 6). 56
In this respect, we have recently described a 'nanoantibiotic' polymer therapeutic, based 57 on dextrin conjugated to colistin, whereby colistin is controllably released from the conjugate 58 by amylase-triggered degradation of dextrin, according to the polymer masked-unmasked 59 protein therapy (PUMPT) principle (7), and in so doing, reinstates the antibiotic activity of 60 colistin (8, 9). These dextrin-colistin conjugates demonstrated antibacterial activity across a 61 range of Gram-negative bacteria that was comparable to colistin methanesulfonate (CMS), 62 but exhibited reduced in vitro and in vivo toxicity and prolonged plasma half-life. 63
In the preliminary design and development of any novel chemical entity it is pivotally important 64 to understand its pharmacokinetic-pharmacodynamic (PK-PD) profile, before moving to in 65 vivo efficacy studies. This is particularly important in nanoantibiotic delivery systems as the 66 incorporation of conventional small molecules into nano-sized structures is associated with 67 4 substantially altered PK-PD properties from the original antibiotic (10, 11). However, the 68 complex release or formation of drug from nanoantibiotics renders conventional PK-PD 69 models inappropriate in the pre-clinical development of these controlled release systems (10, 70 11). Conventional single-compartment static models, whilst extensively utilized to study the 71 effect of fixed antibiotic doses on fixed bacterial loads (12, 13), are typically only viable for 72 <24 h (14, 15), and are of limited value in investigating drug release and real-time 73
antimicrobial effects of controlled release drugs (16, 17). Single compartment 'time to kill' 74 (TTK) models are also unable to prevent denaturation of the macromolecule's activating 75 enzyme (e.g. α-amylase) by artificial media used to sustain bacterial growth (16, 17). Multiple 76 chamber dynamic models may be used to produce concentration gradients, although require 77 considerable technical expertise, specialist software and are associated with high costs (18). 78
In the development and screening of nanoantibiotics, a need, therefore, exists for a suitable in 79 vitro model to define the PK-PD profiles and optimize the characteristics of these novel 80 agents prior to in vivo testing. 81
This study employed dextrin-colistin conjugates as a prototypical nanoantibiotic, to develop 82 a model system which would afford the opportunity to study the in vitro degradation, diffusion 83 and activation of the conjugate, both alone and in the presence of amylase or infected wound 84 fluid. The study sought to define an in vitro model in which the PK-PD parameters of 85 biodegradable antibiotic polymer conjugates could be reliably assessed. 86
87

MATERIALS AND METHODS 88
Materials. Colistin sulfate, ethanol, human salivary α-amylase, 4-dimethylaminopyridine 89 (DMAP), anhydrous N,N-dimethylformamide (DMF), succinic anhydride, diethyl ether, type 1 90 dextrin from corn starch (mol wt ~8,100 g/mol), carbonic anhydrase (29,000 g/mol), were 91 purchased from Sigma Aldrich (Poole, UK conjugates were synthesized and characterized as previously described (8, 9). The dextrin-113 colistin conjugate used in these studies contained dextrin with 1.0 mol% succinoylation and 114 had a mol wt of approximately 10,300 g/mol (gel permeation chromatography (GPC) with 115 pullulan standards) and a colistin content of 11.2% w/w (BCA assay) with < 3% free colistin 116 The same PK-PD setup was used to evaluate the feasibility of dextrin-colistin conjugate 186 unmasking in infected burn wound samples. Each wound fluid sample was diluted 2-fold in 187 PBS to make up the IC volume (5 mL) and dextrin-colistin conjugate (64 µg/mL colistin equiv., time, while protein concentration in the OC increased reciprocally (Fig. 2) . A corresponding 198 increase in antimicrobial activity of the OC over the 48 h incubation was also observed (Fig.  199 2). FPLC demonstrated that, at 48 h, significant unmasking had occurred (p<0.05), with 200 unmasked conjugate accounting for ~68% of total colistin content in the system (Fig. 3) . At 48 201 h there was no significant difference in the distribution of unmasked conjugate between the 202 two compartments (p>0.05). Correspondingly, there was a significantly higher proportion of 203 high molecular weight (masked) dextrin-colistin conjugate in the IC (~80%, p<0.05), 204 compared to the OC (Fig. 3b) . When the experiment was conducted using dextrin-colistin 205 conjugate in the absence of α-amylase, the OC protein content was <10% after 17 h. 206
Membrane integrity testing confirmed the presence of carbonic anhydrase in the OC was 207 always below the lower limit of quantification (data not shown). 208 PK-PD modeling against A. baumannii 7789 isolates. Colistin sulfate, at its MIC (0.0625 209 μg/mL) showed rapid initial killing, and viable bacterial counts were below the assay's lower 210 limit of quantification at 4 h. However, early and significant bacterial re-growth, to the level 211 seen for control, was observed from 8 h onwards (Fig. 4) . Dextrin-colistin conjugate was 212 bactericidal at 2 x MIC, where maximum reduction in viable bacterial counts (~ Log 10 3 213 CFU/mL) occurred at 8 h. Thereafter, re-growth was slower than in the presence of colistin 214 sulfate. In contrast, the colistin sulfate + dextrin-colistin conjugate combination retained 215 reduction in viable bacterial counts at 4 h and sustained reduction of viable bacteria 217 throughout the experiment. The control growth curves confirmed that bacterial growth could 218 be maintained under the experimental conditions, while sterility controls verified that sterility 219 conditions were maintained throughout. Culture onto TSA plates at the end of each 220 experiment confirmed the presence of a homogenous culture. 221 α-Amylase activity in clinical samples. Wound fluid was collected from a total of 6 222 patients (Table 1 ) with partial thickness skin burns. Total protein content in the supernatant 223 was 50.7 ± 15.1 mg/mL (mean ± SD). These studies revealed that α-amylase activity was 224 significantly increased in infected wound fluid (408.4 ± 168.3 IU/L, mean ± SD) compared to 225 patient-matched serum (60.0 ± 25.3 IU/L, mean ± SD) (p<0.05) (Fig. 5) . 226
Unmasking of dextrin-colistin conjugate in infected wound fluid. A time-dependent 227
increase of colistin concentration in the OC was observed in all cases (Fig. 6) . Similarly, 228 concentration of colistin in the OC also increased in the presence of higher α-amylase activity, (28-30) . 267
The ability of the dialysis membrane to retain the intact conjugate within the IC until it is 268 'unmasked' was confirmed during validation, where, in the absence of α-amylase, OC protein 269 content remained <10% at 17 h. The addition of α-amylase, led to an increase in protein 270 content and antimicrobial activity of the OC, which was mirrored by decreased bacterial 271 counts in the TTK study, and were in agreement with previous in vitro physicochemical data 272
Analysis of bacterial counts in the presence of colistin sulfate was interesting and showed 274 that bacterial recovery occurred earlier than the shortest currently recommended dosing 275 interval for colistin (31, 32), demonstrating the clinical benefit that these models may offer. In 276 contrast, with dextrin-colistin conjugate, the recovery of bacterial counts was significantly 277 delayed, presumably due to the sustained release of colistin from dextrin-colistin conjugates 278 by α-amylase. Since colistin is a 'concentration-dependent' antibiotic (33) with a modest post-279 antibiotic effect (34), the ability of the polymer conjugates to prolong exposure of bacteria to 280 colistin may be more beneficial to antibacterial efficacy than achieving high peak 281 concentrations (25, 35, 36) . 
